| Detected | Trial | Change |
|---|---|---|
| 2026-08-11 | NCT07188740 Metformin Inhibits DNMT3A Clonal Hematopoiesis in Acute Leukemia |
Recruitment opened |
| 2026-08-11 | NCT07188740 Metformin Inhibits DNMT3A Clonal Hematopoiesis in Acute Leukemia |
Primary endpoint(s) modified |
| 2026-08-11 | NCT07131059 MRD-positive AML Clinical Study |
Enrollment increased: 120 -> 537 participants |
| 2026-08-11 | NCT07131059 MRD-positive AML Clinical Study |
Trial arms changed: 7 -> 9 |
| 2026-08-11 | NCT07131059 MRD-positive AML Clinical Study |
date change Primary completion pushed: 2026-05-10 -> 2028-05-10 |
| 2026-08-11 | NCT07131059 MRD-positive AML Clinical Study |
date change Completion pushed: 2028-04-30 -> 2028-10-30 |
| 2026-08-11 | NCT06529250 Intermediate-dose HAD Regimen for CEBPA Double-mutated AML |
date change Primary completion pushed: 2026-08-30 -> 2027-08-30 |
| 2026-08-11 | NCT06529250 Intermediate-dose HAD Regimen for CEBPA Double-mutated AML |
date change Completion pushed: 2028-09-01 -> 2029-09-01 |
| 2026-08-09 | NCT06525519 Comparison of Different Dose of Anti-T Lymphocyte Globulin (ATLG) in Haploidentical HSCT… |
overall status: Not Yet Recruiting → Unknown |
| 2026-08-08 | NCT06265545 Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia |
Enrollment increased: 120 -> 458 participants |
| 2026-08-08 | NCT06265545 Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia |
Trial arms changed: 7 -> 8 |
| 2026-08-08 | NCT06265545 Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia |
date change Primary completion pushed: 2026-01-30 -> 2028-01-30 |
| 2026-08-08 | NCT06265545 Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia |
date change Completion pushed: 2026-06-30 -> 2028-06-30 |
| 2026-08-08 | NCT07490288 Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML |
date change Primary completion pushed: 2026-07-01 -> 2026-10-30 |
| 2026-08-08 | NCT07409454 MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly… |
Recruitment opened |
| 2026-08-08 | NCT05632380 ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple… |
date change Primary completion pushed: 2025-10-30 -> 2026-09-30 |
| 2026-08-08 | NCT05632380 ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple… |
date change Completion pushed: 2026-04-30 -> 2026-10-30 |
| 2026-07-25 | NCT06931912 Growth Evaluation, Health Promotion, and Clinical Management in Children and Adolescents… |
overall status: Recruiting → Active, Not Recruiting |
| 2026-07-25 | NCT06931912 Growth Evaluation, Health Promotion, and Clinical Management in Children and Adolescents… |
Primary endpoint(s) modified |
| 2026-07-24 | NCT07493161 Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL |
Primary endpoint(s) modified |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-08-11 | NCT07757672 Salvage Chemotherapy With Sonrotoclax, Cladribine, and Standard-dose Cytarabine… | Phase 1/2 | Not Yet Recruiting |
| 2026-08-11 | NCT07757685 Autologous Hematopoietic Stem Cell Transplantation for Neurological Damage Associated… | Not Yet Recruiting | |
| 2026-08-10 | NCT07754799 A Randomized Phase II Selection Trial of Venetoclax-Based Induction Intensity in Newly… | Phase 2 | Not Yet Recruiting |
| 2026-08-07 | NCT07751471 BCMA/GPRC5D Trispecific Antibody Treatment for Newly Diagnosed Amyloidosis (AL-004) | Phase 2 | Not Yet Recruiting |
| 2026-08-07 | NCT07751588 Plasma ctDNA Monitoring in Pediatric Acute Leukemia | Not Yet Recruiting | |
| 2026-07-24 | NCT07725705 SHR2554 Plus Liposomal Mitoxantrone as First-line Treatment for Peripheral T-cell… | Phase 1/2 | Not Yet Recruiting |
| 2026-07-24 | NCT07726160 A Study of KIV-318 Injection in Patients With BCMA-Positive Relapsed/Refractory Multiple… | Phase 1 | Not Yet Recruiting |
| 2026-07-23 | NCT07723911 A Study of Injectable BLB101 and Blincyto® in Adult Participants With R/R CD19+ B-ALL | Phase 3 | Not Yet Recruiting |
| 2026-07-20 | NCT07714512 Phase I/II Study of Anti-CD38 Monoclonal Antibody in Refractory Severe Aplastic Anemia | Phase 1/2 | Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT05888870 | ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults… | Hemophilia A With Inhibitor | Recruiting |
| NCT05849740 | An Exploratory Study of Cluster of Differentiation 38 (CD38) Monoclonal Antibody Combined… | Acquired Hemophilia | Recruiting |
| NCT07406139 | PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A） | Hemophilia | Recruiting |
| NCT04518475 | Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune… | Primary Immune Thrombocytopenia (ITP) | Recruiting |
| Phase 3 | |||
| NCT07152041 | Newly-diagnosed Pediatric Ph-positive B-ALL Protocol | Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+) | Recruiting |
| NCT07132684 | Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia… | AML, Adult | Recruiting |
| NCT06744504 | Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid… | AML | Recruiting |
| NCT06613035 | Twice-per-weekSelinexor, 2 Days Melphalan | Acute Myeloid Leukemia | Not Yet Recruiting |
| NCT06888479 | Optimal Timing of Hepatitis B Vaccination After Transplants | Transplant-Related Disorder | Not Yet Recruiting |
| NCT03021330 | Efficacy of Intermediate-Dose Cytarabine Induction Regimen in Adult AML | AML | Active, Not Recruiting |
| NCT07407140 | VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated… | AML, Adult | Not Yet Recruiting |
| NCT07539818 | Azacitidine + Venetoclax VS Azacitidineas Maintenance Therapy in AML | AML | Not Yet Recruiting |
| NCT07588945 | daGOAT-Guided Prevention of Severe aGVHD After Allo-HSCT | Transplant-Related Disorder | Not Yet Recruiting |
| NCT07686965 | Lisaftoclax Plus Azacitidine Maintenance After Allogeneic Hematopoietic Stem Cell… | Acute Myeloid Leukemia (AML) | Not Yet Recruiting |
| NCT07723911 | A Study of Injectable BLB101 and Blincyto® in Adult Participants With R/R CD19+ B-ALL | Precursor B-cell Acute Lymphoblastic Leukemia | Not Yet Recruiting |
| Phase 2/3 | |||
| NCT06855810 | Newly-diagnosed Pediatric T-cell ALL Protocol | Acute Lymphoblastic Leukemia | Recruiting |
| NCT06882057 | Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol | Acute Lymphoblastic Leukemia ALL | Recruiting |
| NCT06764238 | Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol | Acute Lymphoblastic Leukemia ALL | Recruiting |
| NCT05356169 | Intensive Therapy Combined With Venetoclax for Adult Acute Myeloid Leukemia | Acute Myeloid Leukemia | Active, Not Recruiting |
| NCT07278908 | Avatrombopag Combined With All-trans Retinoic Acid in the Treatment of Primary Immune… | ITP - Immune Thrombocytopenia | Not Yet Recruiting |
| Phase 2 | |||
| NCT03980002 | A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in… | Chronic Lymphocytic Leukemia | Recruiting |
| NCT05846750 | Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone… | Marginal Zone Lymphoma | Recruiting |
| NCT06158269 | DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma | Multiple Myeloma | Recruiting |
| NCT06254560 | Rituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness | Severe Aplastic Anemia | Recruiting |
| NCT05925504 | The Tapering Dose of Luspatercept in Patients With Lower-risk Myelodysplastic Syndromes | Lower Risk MDS Per IPSS-R | Recruiting |